Board of Directors

Paul MacLeman, Chairman

MBA, DVM, Grad Dip Eng, Cert Eng, FAICD

Paul is a veterinarian by training and has worked in the life-science sectorfor over 25 years. With a career-spanning veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance, Paul has expertise in capital raising, business development, technology commercialisation and sales & marketing globally.

He has founded life sciences start-ups and worked in investment banking focusing on the analysis and financing of technology companies. Paul has previously served as Chairman, Director or Managing Director/CEO of several VC funded, ASX, NASDAQ, CSE and TSX listed companies. Paul is currently Executive Chairman of Island Pharmaceuticals Ltd (ILA.ASX), and led the company’s IPO that was 6x oversubscribed. He is Chairman of AdAlta Limited (1AD:ASX) and Supertrans Medical Pty Ltd and Non-Executive Director of Upkara Pty Limited. Paul Chairs the Industry Review Committee for the Pharmaceutical Manufacturing National Training Package for the AISC. He is an expert advisor to PharmaVentures (Oxford, UK) and Mind Medicine. Paul also serves on a number of other NFP and government advisory groups

 

…………………………………………………………………………………………………………………………………………………………………………………………………………………………………………….

Graeme Wald, Managing Director

B.SC Hons. PhD. MBA. GAICD

Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team.  In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in then sector and was Chairman of the Risk & Audit Committee of Nexvet while a director of the company through to its NASDAQ listing. He was founding Chairman of Prota Therapeutics and acting CEO.

 

 


Colin Goodchild, Executive Director

MA (Cantab), MB, BChir, PhD, FRCA, FANZCA, FFPMANZCA

colin-goodchildColin is a co‐founder of Drawbridge and serves as Chief Medical Officer. He is a UK medical graduate from Cambridge University with a PhD in neuroscience from the University of Leeds. He is a specialist in anaesthesia & pain medicine and holds post graduate diplomas from the Royal College of Anaesthetists in London, UK and also from the Australia & NZ College of Anaesthetists and its Faculty of Pain Medicine. He has published in excess of 100 publications in major international journals in his field.

Colin is very active clinically in providing anaesthesia for surgery and as a tertiary referral Pain Medicine Specialist. He is well known as an inventor in anaesthesia and analgesia being listed inventor on 17 patents which have been licensed for development and commercialisation to various companies including: Purdue Frederick; Vernalis; Balboa Biosciences; and CNSBio.  He has held the positions of Director and CSO at CNSBio Pty Ltd. Colin is recognised as a leader in translational medicine, combining knowledge and skills as a neuroscientist, clinician, practising anaesthetist and entrepreneur.

Click for Researchgate profile